Royal Bank Of Canada Issues Pessimistic Forecast for Johnson & Johnson (NYSE:JNJ) Stock Price

Johnson & Johnson (NYSE:JNJ) had its price target lowered by research analysts at Royal Bank Of Canada from $290.00 to $280.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target suggests a potential upside of 11.65% from the stock’s current price.

JNJ has been the topic of several other research reports. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research note on Monday, August 3rd. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a research report on Wednesday, July 15th. Weiss Ratings raised Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 8th. JPMorgan Chase & Co. boosted their target price on Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 29th. Finally, Scotiabank reissued an “outperform” rating and set a $305.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $273.30.

Johnson & Johnson Trading Up 0.9%

Johnson & Johnson stock opened at $250.78 on Wednesday. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07. The firm’s 50 day moving average price is $265.89 and its 200-day moving average price is $249.37. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The stock has a market cap of $604.35 billion, a P/E ratio of 28.96, a PEG ratio of 2.70 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. Johnson & Johnson’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts predict that Johnson & Johnson will post 11.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 87,569 shares of company stock valued at $23,064,544 over the last quarter. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

Hedge funds have recently added to or reduced their stakes in the company. Silver Coast Investments LLC lifted its position in Johnson & Johnson by 3.8% in the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock valued at $271,000 after purchasing an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV boosted its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock valued at $1,630,000 after purchasing an additional 39 shares during the period. Triumph Capital Management grew its position in Johnson & Johnson by 1.6% in the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock worth $643,000 after purchasing an additional 39 shares during the last quarter. Kwmg LLC grew its position in Johnson & Johnson by 1.7% in the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company’s stock worth $631,000 after purchasing an additional 39 shares during the last quarter. Finally, Denali Advisors LLC increased its stake in shares of Johnson & Johnson by 1.2% in the second quarter. Denali Advisors LLC now owns 3,305 shares of the company’s stock valued at $839,000 after purchasing an additional 40 shares during the period. 69.55% of the stock is currently owned by institutional investors.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported third-quarter adjusted EPS of $2.59, ahead of the $2.53 consensus, while revenue increased 5.9% year over year to $25.4 billion, roughly matching expectations. Johnson & Johnson earnings results
• Positive Sentiment: Management raised its 2026 outlook to $101.0 billion-$101.4 billion in revenue and $11.05-$11.15 in adjusted EPS. Innovative Medicine was the key growth driver, including strong oncology results and rapid TREMFYA growth. Johnson & Johnson Q3 results and guidance
• Positive Sentiment: The company declared a quarterly dividend of $1.34 per share, or $5.36 annualized, reinforcing JNJ’s appeal as an income-oriented healthcare stock. Johnson & Johnson quarterly dividend
• Neutral Sentiment: Johnson & Johnson is considering a mid-2027 spinoff of its hips-and-knees orthopedic business. A separation could sharpen the company’s portfolio focus, but it also highlights ongoing challenges in the medical-device operation. J&J hips-and-knees business spinoff
• Negative Sentiment: MedTech grew only about 2.5% operationally and missed expectations, with weakness in surgery and cardiovascular products, particularly outside the United States. Investors viewed the shortfall as more important than the pharmaceutical strength. Johnson & Johnson MedTech weakness
• Negative Sentiment: Reported profit plunged because of one-time costs tied largely to the proposed talc litigation resolution, as well as acquisitions and collaborations. GAAP EPS fell to $0.09 from $2.80 a year earlier, overshadowing the adjusted earnings beat. Johnson & Johnson quarterly report analysis
• Negative Sentiment: The guidance increase was modest relative to elevated investor expectations, while Erste Group reduced its FY2027 EPS estimate to $12.65 from $12.83, adding to concerns about future earnings growth.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.